Table 1.
Strategies to inhibit the inflammasome pathways associated with pyroptosis of diabetic kidney disease.
| Medication or treatment | Effects on renal tissues | Reference |
|---|---|---|
| Quercetin and allopurinol | Inhibiting caspase-1/IL-1β/IL-18 axis | (105) |
| Cepharanthine and piperine | Inhibiting NF-κB and NLRP3 inflammasome activation | (106) |
| Guava and trehalose | Inhibiting IL-1β | (109) |
| Punicalagin | Inhibiting TXNIP/NLRP3 signaling | (110) |
| CCPA (A1AR agonist) | Inhibiting caspase-1/IL-18 | (113) |
| TAK-242 | Inhibiting TLR4/NF-κB signaling | (116) |
| Parthenolide | Inhibiting NF-κB | (116) |
| Geniposide | Inhibiting AMPK/SIRT1/NF-κB signaling | (119) |
| Silencing KCNQ1OT1 | Upregulating the expression of miR-506-3p | (123) |
| GAS5 | Reducing the expression of miR-452-5p | (124) |
These studies do not prove that pyroptosis is necessarily related to DKD and the mechanism needs further elucidation.